

The PAVING II Interview study: Assessing Evolving Patient Preferences Regarding Gene Therapy for Haemophilia Patients

Jolien Broekmans¹, Quentin Van Thillo^{2,3}, Phaedra Locquet¹, Brett Hauber⁴, Peter Verhamme^{3,5}, Tom Adriaenssens^{3,5}, Peter Sinnaeve^{3,5}, Isabelle Huys¹

¹ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium


² Haemophilia Centre, University Hospitals Leuven, Leuven, Belgium

³ Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium

⁴ Pfizer, Inc, New York, NY, USA.

⁵ Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium

BACKGROUND & OBJECTIVES



Aim: Assess the **evolution** of patient **preferences** regarding **gene therapy (GT)** since European Medicines Agency (EMA) approval.

METHODS

🗣 Semi-structured **interviews** (n=14) with Belgian:

- Haemophilia A patients (n=8)
- Haemophilia B patients (n=4)
- Haemophilia patients that received GT (n=2)

📝 Ad verbatim transcription of interviews

🔍 Thematic **framework analysis** using Nvivo Software


PRELIMINARY RESULTS

i) Participant characteristics

Characteristics	Percentage (%)
Age, > 40 years	50.0
Region, Flanders	85.7
Disease severity, severe	85.7
Joint damage, severe	57.1
Current treatment, prophylaxis	85.7
Treatment satisfaction, very satisfied	57.1
Bleeding frequency, < 2/year	78.6

ii) Comparing PAVING I with PAVING II

Baseline knowledge GT:




- Most participants had already **heard of GT**
- Self-reported **baseline knowledge** varied
- **42.9%** reported their knowledge as '**Reasonable**'
- **PAVING I:** slightly **more patients** who rated their knowledge as '**Good**'

Willingness to receive GT:



- Compared to PAVING I:
 - **Smaller** proportion were **very willing**
 - **Larger** proportion were **willing or neutral**

iii) Treatment attributes of PAVING I vs. PAVING II



Experiences of patients who received GT

- **Improved QoL**
- **High motivation** (benefits > risks)
- **Corticosteroid treatment** (tough but manageable)
- **Newer non-factor therapies** (attractive alternatives)

ABBREVIATIONS

GT = Gene Therapy, EMA = European Medicines Agency, QoL = Quality of Life

ACKNOWLEDGEMENTS

This work is supported by the KU Leuven and part of the C3-Project (C3/22/052). We would like to thank all patients that participated in this project.

CONCLUSION

These preliminary findings indicate that the **main priorities** in treatment attributes **stayed the same** compared to PAVING I, but there are **some shifts** in less prioritized attributes. Overall, patients are **very satisfied** with current **standard of care**.